[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Rajalakshmi V, Chandran P, Selvambigai, Ganesh J: Metanephric stromal tumor: a novel pediatric renal neoplasm. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):389-91
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric stromal tumor: a novel pediatric renal neoplasm.
  • Metanephric stromal tumor of kidney is a novel pediatric benign stromal specific renal neoplasm.
  • This tumor is usually centered in the renal medulla with a characteristic microscopic appearance which differentiates this lesion from congenital mesoblastic nephroma and clear cell sarcoma of the kidney.
  • The differentiation of metanephric stromal tumor from clear cell sarcoma of the kidney will spare the child from the ill effects of adjuvant chemotherapy.
  • In this communication we describe the gross and microscopic features of metanephric stromal tumor in a one-month-old child with good prognosis.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry. Humans. Infant, Newborn. Nephroma, Mesoblastic / diagnosis. Sarcoma, Clear Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679970.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Balaguer Guill J, Fernández Navarro JM, Cañete Nieto A, Muro Velilla MD, Hernández Martí M, Castel Sánchez V: [Renal tumors in infants aged less than 1 year]. An Pediatr (Barc); 2006 May;64(5):433-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumores renales en niños menores de un año.
  • OBJECTIVE: To determine the frequency and distribution of primary renal tumors diagnosed in a pediatric oncology unit in children younger than 1 year and identify their clinical and histopathological characteristics, the treatment used, and outcomes.
  • MATERIAL AND METHODS: We retrospectively reviewed the medical records of infants with primary tumors of the kidney diagnosed between January 1972 and February 2003.
  • RESULTS: A total of 137 tumors were diagnosed in our unit during the period studied.
  • The most prevalent tumor in this age group was Wilms' tumor (WT) in 15 patients, followed by mesoblastic nephroma (MN) in 9 patients and rhabdoid tumor in 1 patient.
  • The mean age at diagnosis of WT was 4.8 months (range: 1 day-11 months), with a median of 5.03 months.
  • The median age at diagnosis of MN was 1 day (range: 1 day-3 months).
  • Presenting symptoms consisted of abdominal mass in 20 patients, hematuria in 4 patients and intestinal pseudo-occlusion (MN) in 1 patient.
  • High blood pressure was found in 12 of the 25 patients.
  • Among the 15 WT, 9 were stage I, 1 was stage II, one was stage III, 2 were stage IV, and 1 was stage V.
  • One patient died before surgery.
  • Overall survival at 5 years was 0.67 (SE 0.12) for WT and 0.89 (SE 0.1) for MN, respectively, with a mean follow-up of 290 months.
  • CONCLUSIONS: MN was more frequent than WT in infants aged less than 6 months.
  • The first-line therapy in these patients is surgery since this type of tumor shows little chemosensitivity and chemotherapy is poorly tolerated in infants.
  • [MeSH-minor] Female. Humans. Infant. Infant, Newborn. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756884.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. López Almaraz R, Villafruela Alvarez C, Rodríguez Luis J, Doménech Martínez E: [Neonatal neoplasms: a single-centre experience]. An Pediatr (Barc); 2006 Dec;65(6):529-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neoplasias neonatales: experiencia de un centro.
  • INTRODUCTION: Malignant tumors are uncommon in the neonatal period and benign tumors may have malignant potential.
  • OBJECTIVES: To describe the neoplasms diagnosed and treated in newborns (</= 28 days of life) in the Hospital Universitario de Canarias and their association with congenital abnormalities and to evaluate prenatal diagnosis of these tumors.
  • The variables analyzed were the percentage of neonatal neoplasms among the total number of cancer cases in children aged less than 14 years, their incidence among all the newborns in our hospital, sex, year of diagnosis, age at clinical diagnosis, the presence or absence of prenatal diagnosis, type of tumor (histologic diagnosis), association with syndromes or other congenital anomalies, treatment, and long-term outcome.
  • RESULTS: Of 260 neoplasms diagnosed in our unit from 1980, 16 (6.1 %) were diagnosed in the neonatal period.
  • Males accounted for 43.8 % and females for 56.2 %, with a mean age at diagnosis of 5.5 days (range 1-28 days).
  • Five neonates (31.2 %) had a prenatal diagnosis, 60 % of which were made in the last 7 years of the study period.
  • Histologic diagnoses were neuroblastoma (n = 5; 31.2 %), teratoma/ germ cell tumor (n = 4; 25 %), soft tissue sarcoma (one fibrosarcoma of the thigh and two hemangiopericytoma of the back and heart; 18.8 %), and one case each of mesoblastic nephroma, cerebral tumor (ependymoblastoma), melanoma (associated with giant congenital melanocytic nevi), and acute leukemia (associated with Down syndrome).
  • Treatment consisted of surgery alone (n = 10; 62.5 %) and surgery plus chemotherapy (n = 5; 31.2 %); one patient received no treatment.
  • CONCLUSIONS: The neoplasms most frequently diagnosed in the neonatal period were solid tumors, mainly neuroblastoma and teratomas/germ cell tumors; 12.5 % were associated with syndromes or congenital anomalies.
  • In the last 7 years, the prenatal diagnosis of these entities has improved.
  • Most of the neoplasms responded to therapy, mainly surgery, and long-term outcome was favorable.
  • [MeSH-minor] Female. Humans. Infant, Newborn. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2007 Jul;67(1):85-6 [17663916.001]
  • (PMID = 17194321.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Dessars B, De Raeve LE, Morandini R, Lefort A, El Housni H, Ghanem GE, Van den Eynde BJ, Ma W, Roseeuw D, Vassart G, Libert F, Heimann P: Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol; 2009 Jan;129(1):139-47
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.
  • Large congenital melanocytic nevi (CMNs) are said to have a higher propensity to malignant transformation compared with acquired nevi.
  • We have performed genotypic (karyotype, fluorescence in situ hybridization, and mutational analyses) and differential expression studies on a large cohort of medium (n=3) and large (n=24) CMN.
  • Mutational screening showed a high frequency of NRAS mutations in our series (19/27 cases, 70%), whereas BRAF mutations were less common (4/27 cases, 15%).
  • Differential did not show significant alterations of cellular processes such as cell proliferation, cell migration/invasion, angiogenesis, apoptosis, and immune/inflammatory responses.
  • Furthermore, the observed alterations linked to chemoresistance might partially account for the well-known inefficacy of chemotherapy in malignant melanoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Melanocytes / metabolism. Nevus, Pigmented / genetics. Nevus, Pigmented / metabolism
  • [MeSH-minor] Cell Movement. Cell Proliferation. Chromosome Aberrations. Cohort Studies. DNA Mutational Analysis. Genotype. Humans. In Situ Hybridization. In Situ Hybridization, Fluorescence. Karyotyping. Neoplasm Invasiveness. Neovascularization, Pathologic


5. Bisceglia M, Carosi I, Vairo M, Zaffarano L, Bisceglia M, Creti G: Congenital mesoblastic nephroma: report of a Case with review of the most significant literature. Pathol Res Pract; 2000;196(3):199-204
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital mesoblastic nephroma: report of a Case with review of the most significant literature.
  • AIMS AND BACKGROUND: Congenital mesoblastic nephroma (CMN) is a rare pediatric tumor of the kidney with the highest peak of incidence during the first 3 postnatal months.
  • It has previously been confused with Wilms' tumor (which, on the contrary, is rare during the first six months of age and is still considered a histogenetic congener).
  • CMN almost always has a favourable prognosis.
  • Therefore, CMN needs to be correctly diagnosed and differentiated from other pediatric renal neoplasms.
  • Two morphological subtypes are currently distinguished histologically: the classical or leiomyomatous type and the atypical or cellular type.
  • Mixed forms with a combination of the two patterns are also on record.
  • Recurrence and even tumor-related death have been described in the literature and always related to the atypical form or to the mixed form, particularly in patients aged more than 3 months and in those cases in which the surgical removal was not complete.
  • Opinions concerning post-surgical clinical management, especially in regard to adjuvant therapy, are not unanimous.
  • METHODS: A case of CMN, predominantly of the classical histological subtype diagnosed in a baby with a follow-up of 6 years, is herein presented.
  • The tumor was discovered at birth and surgically removed after one month.
  • Since the tumor showed a high mitotic index (one of the characteristics of the cellular subtype) and the perirenal fat was focally involved with the tumor, the possibility of giving adjuvant chemotherapy was considered.
  • Flow cytometric analysis was also performed which showed a diploid DNA content of neoplastic cells.
  • RESULTS: The tumor was completely removed, surgical margins were free histologically, and no clear-cut histological features of the atypical subtype were noted.
  • Consequently no additional therapy was given.
  • Six years after surgery the patient is developing well and is free of disease.
  • CONCLUSIONS: CMN almost always pursues a benign clinical course if diagnosed under three months of age and if totally surgically excised independent of histological type.
  • Criteria for management of atypical cases are not unanimous in regard to the benefit of additional therapy after surgery.
  • [MeSH-major] Kidney Neoplasms / congenital. Nephroma, Mesoblastic / congenital
  • [MeSH-minor] Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Diploidy. Female. Flow Cytometry. Humans. Immunohistochemistry. Infant, Newborn. Mitotic Index. Treatment Outcome

  • Genetic Alliance. consumer health - Congenital Mesoblastic Nephroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10729925.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 73
  •  go-up   go-down


6. Jones C, Rodriguez-Pinilla M, Lambros M, Bax D, Messahel B, Vujanic GM, Reis-Filho JS, Pritchard-Jones K: c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. J Clin Pathol; 2007 Nov;60(11):1226-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To investigate the presence and prognostic relevance of KIT expression in paediatric renal tumours, and to determine whether receptor overexpression is associated with gene amplification and/or mutation.
  • METHODS: Immunohistochemistry without antigen retrieval for CD117 was carried out on tissue microarrays consisting of 274 Wilms' tumours, 13 clear cell sarcomas of the kidney (CCSK), 10 mesoblastic nephromas (MN), and 7 rhabdoid tumours of the kidney (RTK).
  • RESULTS: Only 8/200 (4.0%) Wilms' tumours exhibited any degree of moderate-strong KIT staining in any of their assessable cell types.
  • This small group of KIT-positive tumours had a shorter time to relapse (p = 0.0044, log-rank test).
  • CONCLUSIONS: KIT overexpression in rare in Wilms' tumours, although does appear to confer a worse prognosis, in particular for patients primarily treated with preoperative chemotherapy.
  • CCSKs are associated with an increased expression of KIT, however, in the absence of gene amplification and/or activating mutation.
  • The potential of anti-KIT therapeutic strategies in the treatment of paediatric renal tumours appears to be limited.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Kidney Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Sarcoma, Clear Cell / metabolism. Wilms Tumor / metabolism
  • [MeSH-minor] Antineoplastic Agents. Child. DNA Mutational Analysis. DNA, Neoplasm / genetics. Gene Amplification. Humans. In Situ Hybridization / methods. Neoadjuvant Therapy. Nephrectomy. Prognosis. Survival Analysis. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1037-51 [10582338.001]
  • [Cites] Cell Oncol. 2007;29(5):399-408 [17726262.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):486-92 [11914627.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):325-7 [12645332.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):339-45 [12645334.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1293-9 [13679437.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):37-46 [14700607.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):468-73 [14752069.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):463-6 [15113851.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6139-43 [1384954.001]
  • [Cites] Virchows Arch. 1994;424(2):135-41 [7514077.001]
  • [Cites] J Histochem Cytochem. 1994 Nov;42(11):1417-25 [7523489.001]
  • [Cites] Hum Pathol. 1998 May;29(5):498-504 [9596274.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] Diagn Cytopathol. 2005 Oct;33(4):228-32 [16138375.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):7986-94 [16299227.001]
  • [Cites] Cell Oncol. 2005;27(5-6):319-26 [16373964.001]
  • [Cites] Lab Invest. 2006 Apr;86(4):398-408 [16446704.001]
  • [Cites] J Pathol. 2006 Sep;210(1):49-58 [16823893.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11148-55 [17145858.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):4-18 [10632483.001]
  • (PMID = 17965221.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 11886
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2095465
  •  go-up   go-down


7. Tirkey N, Kaur G, Vij G, Chopra K: Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol; 2005;5:15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In India, Curcumin (CMN) is popularly known as "Haldi", and has been well studied due to its economic importance.
  • Traditional Indian medicine claims the use of its powder against biliary disorders, anorexia, coryza, cough, diabetic wounds, hepatic disorder, rheumatism and sinusitis.
  • This study was designed to examine the possible beneficial effect of CMN in preventing the acute renal failure and related oxidative stress caused by chronic administration of cyclosporine (CsA) in rats.
  • CMN was administered concurrently with CsA (20 mg/kg/day s.c) for 21 days.
  • Oxidative stress in kidney tissue homogenates was estimated using thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH) content, superoxide dismutase (SOD), and Catalase (CAT).
  • Nitrite levels were estimated in serum and tissue homogenates.
  • RESULTS: CsA administration for 21 days produced elevated levels of TBARS and marked depletion of renal endogenous antioxidant enzymes and deteriorated the renal function as assessed by increased serum creatinine, Blood Urea Nitrogen (BUN) and decreased creatinine and urea clearance as compared to vehicle treated rats.
  • CMN markedly reduced elevated levels of TBARS, significantly attenuated renal dysfunction increased the levels of antioxidant enzymes in CsA treated rats and normalized the altered renal morphology.
  • CONCLUSION: In conclusion our study showed that CMN through its antioxidant activity effectively salvaged CsA nephrotoxicity.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Curcumin / pharmacology. Cyclosporine / antagonists & inhibitors. Immunosuppressive Agents / antagonists & inhibitors. Kidney / drug effects. Kidney Diseases / drug therapy
  • [MeSH-minor] Animals. Female. Kidney Function Tests. Male. Oxidative Stress / drug effects. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. CURCUMIN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1978 Feb;186(1):189-95 [24422.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Antioxid Redox Signal. 2005 Jan-Feb;7(1-2):32-41 [15650394.001]
  • [Cites] Pharmazie. 2005 Jan;60(1):57-61 [15700780.001]
  • [Cites] Science. 1992 Dec 18;258(5090):1898-902 [1281928.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2144-9 [8486781.001]
  • [Cites] J Clin Invest. 1993 Oct;92(4):1859-65 [8408638.001]
  • [Cites] Immunol Today. 1994 Jan;15(1):7-10 [8136014.001]
  • [Cites] J Nat Prod. 1994 Feb;57(2):230-5 [8176399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7350-4 [7518929.001]
  • [Cites] Transplant Proc. 1994 Oct;26(5):2902-7 [7940917.001]
  • [Cites] Transplantation. 1994 Dec 27;58(12):1371-8 [7809931.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):259-66 [7812955.001]
  • [Cites] Mol Cell Biochem. 1994 Aug 17;137(1):1-8 [7845373.001]
  • [Cites] J Pharm Pharmacol. 1994 Dec;46(12):1013-6 [7714712.001]
  • [Cites] Kidney Int. 1995 Mar;47(3):927-34 [7752594.001]
  • [Cites] Cancer Lett. 1995 Jul 20;94(1):79-83 [7621448.001]
  • [Cites] Mol Cell Biochem. 1995 May 10;146(1):35-7 [7651374.001]
  • [Cites] Mol Cell Biochem. 1995 Oct 18;151(2):131-40 [8569758.001]
  • [Cites] Kidney Int Suppl. 1995 Dec;52:S70-4 [8587288.001]
  • [Cites] Biochem Biophys Res Commun. 1996 May 6;222(1):71-7 [8630077.001]
  • [Cites] Arzneimittelforschung. 1996 Feb;46(2):169-71 [8720307.001]
  • [Cites] Br J Pharmacol. 1996 Jun;118(4):885-92 [8799558.001]
  • [Cites] Eur J Pharmacol. 1996 Jun 13;306(1-3):265-70 [8813640.001]
  • [Cites] J Pharm Pharmacol. 1997 Jan;49(1):105-7 [9120760.001]
  • [Cites] Exp Nephrol. 1997 Jan-Feb;5(1):23-30 [9052845.001]
  • [Cites] Hypertension. 1997 Mar;29(3):822-7 [9052902.001]
  • [Cites] Transplant Proc. 1997 Feb-Mar;29(1-2):1241-3 [9123290.001]
  • [Cites] Clin Chim Acta. 1997 Aug 8;264(1):1-12 [9267698.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Apr;293(1):75-81 [10734155.001]
  • [Cites] Kidney Int. 2000 Apr;57(4):1549-59 [10760090.001]
  • [Cites] Med Res Rev. 2000 Sep;20(5):323-49 [10934347.001]
  • [Cites] Int J Antimicrob Agents. 2000 Dec;16(4):415-7 [11118850.001]
  • [Cites] FEBS Lett. 2002 Apr 10;516(1-3):191-6 [11959131.001]
  • [Cites] Phytomedicine. 2002 Apr;9(3):232-8 [12046864.001]
  • [Cites] Anal Biochem. 1982 Oct;126(1):131-8 [7181105.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(23):8222-6 [3865224.001]
  • [Cites] Int J Clin Pharmacol Ther Toxicol. 1986 Dec;24(12):651-4 [3546166.001]
  • [Cites] Ann Clin Lab Sci. 1989 Jul-Aug;19(4):238-41 [2667454.001]
  • [Cites] N Engl J Med. 1989 Dec 21;321(25):1725-38 [2687689.001]
  • [Cites] Pharmacol Rev. 1990 Sep;41(3):423-34 [2185493.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1990 May;68(2):189-203 [2162073.001]
  • [Cites] Transplant Proc. 1987 Feb;19(1 Pt 2):1193 [3152624.001]
  • [Cites] Planta Med. 1991 Feb;57(1):1-7 [2062949.001]
  • [Cites] Ann Neurol. 1992 Sep;32(3):297-311 [1384420.001]
  • [Cites] J Clin Invest. 1992 Dec;90(6):2593-7 [1334979.001]
  • [Cites] Lipids. 1997 Nov;32(11):1173-80 [9397403.001]
  • [Cites] Transplantation. 1998 Jul 27;66(2):147-52 [9701255.001]
  • [Cites] Biochem Pharmacol. 1998 Jun 15;55(12):1955-62 [9714315.001]
  • [Cites] Am J Physiol. 1998 Oct;275(4 Pt 2):F595-604 [9755131.001]
  • [Cites] Kidney Int. 1999 Jun;55(6):2407-14 [10354289.001]
  • [Cites] Int J Tissue React. 1999;21(1):7-11 [10463135.001]
  • [Cites] Mol Pharmacol. 1999 Sep;56(3):455-63 [10462532.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jul 5;295(1):62-6 [12083767.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3868-75 [12097302.001]
  • [Cites] Ren Fail. 2002 May;24(3):259-74 [12166693.001]
  • [Cites] Pharmacol Toxicol. 2003 Jan;92(1):33-8 [12710595.001]
  • [Cites] Phytother Res. 2003 May;17(5):481-4 [12748983.001]
  • [Cites] Free Radic Biol Med. 2003 Sep 1;35(5):475-84 [12927597.001]
  • [Cites] Phytother Res. 2003 Sep;17(8):925-9 [13680826.001]
  • [Cites] J Biosci. 2003 Dec;28(6):715-21 [14660871.001]
  • [Cites] Life Sci. 2004 Jan 9;74(8):969-85 [14672754.001]
  • [Cites] Mol Cell Biochem. 2003 Dec;254(1-2):289-97 [14674708.001]
  • [Cites] Free Radic Biol Med. 2003 Dec 15;35(12):1632-44 [14680686.001]
  • [Cites] Biol Pharm Bull. 2004 Feb;27(2):170-3 [14758027.001]
  • [Cites] Pharmacology. 1974;11(3):151-69 [4831804.001]
  • (PMID = 16225695.001).
  • [ISSN] 1471-2210
  • [Journal-full-title] BMC pharmacology
  • [ISO-abbreviation] BMC Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; IT942ZTH98 / Curcumin
  • [Other-IDs] NLM/ PMC1277828
  •  go-up   go-down


8. Kaur G, Tirkey N, Bharrhan S, Chanana V, Rishi P, Chopra K: Inhibition of oxidative stress and cytokine activity by curcumin in amelioration of endotoxin-induced experimental hepatoxicity in rodents. Clin Exp Immunol; 2006 Aug;145(2):313-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of oxidative stress and cytokine activity by curcumin in amelioration of endotoxin-induced experimental hepatoxicity in rodents.
  • The present study is aimed at investigating the effect of curcumin (CMN) in salvaging endotoxin-induced hepatic dysfunction and oxidative stress in the liver of rodents.
  • Hepatotoxicity was induced by administering lipopolysaccharide (LPS) in a single dose of 1 mg/kg intraperitoneally to the animals, which were being treated with CMN daily for 7 days.
  • Oxidative stress in liver tissue homogenates was estimated by measuring thiobarbituric acid reactive substances (TBARS), glutathione (GSH) content and superoxide dismutase (SOD) activity.
  • Serum and tissue nitrite was estimated using Greiss reagent and served as an indicator of NO production.
  • A separate set of experiments was performed to estimate the effect of CMN on cytokine levels in mouse serum after LPS challenge.
  • CMN administration attenuated these effects of LPS successfully.
  • Further CMN treatment also regressed various structural changes induced by LPS in the livers of rats and decreased the levels of tumour necrosis factor-alpha and interleukin-6 in mouse plasma.
  • In conclusion, these findings suggest that CMN attenuates LPS-induced hepatotoxicity possibly by preventing cytotoxic effects of NO, oxygen free radicals and cytokines.
  • [MeSH-major] Curcumin / pharmacology. Cytokines / immunology. Hepatitis, Animal / drug therapy. Immunosuppressive Agents / pharmacology
  • [MeSH-minor] Animals. Glutathione / analysis. Interleukin-1 / analysis. Interleukin-6 / analysis. Lipid Peroxidation. Lipopolysaccharides. Liver / pathology. Liver / physiopathology. Liver Function Tests. Male. Nitrites / analysis. Nitrites / blood. Oxidative Stress / drug effects. Rats. Rats, Wistar. Superoxide Dismutase / analysis. Tumor Necrosis Factor-alpha / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 1990 Aug;162(2):421-7 [2373872.001]
  • [Cites] J Biol Chem. 1991 Mar 5;266(7):4244-50 [1847917.001]
  • [Cites] Planta Med. 1991 Feb;57(1):1-7 [2062949.001]
  • [Cites] Biochem Pharmacol. 1991 Aug 8;42(5):1129-35 [1872897.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):347-61 [1538588.001]
  • [Cites] Eicosanoids. 1992;5 Suppl:S42-4 [1449830.001]
  • [Cites] Am J Physiol. 1993 Apr;264(4 Pt 1):G801-9 [8476062.001]
  • [Cites] Hepatology. 1994 Feb;19(2):480-8 [8294104.001]
  • [Cites] Circ Shock. 1994 Jan;42(1):53-8 [8149510.001]
  • [Cites] Lipids. 1997 Nov;32(11):1173-80 [9397403.001]
  • [Cites] Biochem Pharmacol. 1998 Jun 15;55(12):1955-62 [9714315.001]
  • [Cites] J Nat Prod. 1994 Feb;57(2):230-5 [8176399.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):259-66 [7812955.001]
  • [Cites] Mol Cell Biochem. 1994 Aug 17;137(1):1-8 [7845373.001]
  • [Cites] J Pharm Pharmacol. 1994 Dec;46(12):1013-6 [7714712.001]
  • [Cites] Cancer Lett. 1995 Jul 20;94(1):79-83 [7621448.001]
  • [Cites] Mol Cell Biochem. 1995 May 10;146(1):35-7 [7651374.001]
  • [Cites] Arzneimittelforschung. 1996 Feb;46(2):169-71 [8720307.001]
  • [Cites] Mol Pharmacol. 1996 Aug;50(2):277-84 [8700134.001]
  • [Cites] Eur J Pharmacol. 1995 Dec 7;293(4):327-34 [8748685.001]
  • [Cites] J Leukoc Biol. 1996 Oct;60(4):487-92 [8864133.001]
  • [Cites] J Pharm Pharmacol. 1997 Jan;49(1):105-7 [9120760.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jun;293(3):968-72 [10869399.001]
  • [Cites] Med Res Rev. 2000 Sep;20(5):323-49 [10934347.001]
  • [Cites] Int J Antimicrob Agents. 2000 Dec;16(4):415-7 [11118850.001]
  • [Cites] Nitric Oxide. 2002 Feb;6(1):18-28 [11829531.001]
  • [Cites] Phytomedicine. 2002 Apr;9(3):232-8 [12046864.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jul 5;295(1):62-6 [12083767.001]
  • [Cites] Hepatology. 2002 Jul;36(1):55-64 [12085349.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3868-75 [12097302.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G256-65 [12121871.001]
  • [Cites] Bioorg Med Chem Lett. 1998 Nov 3;8(21):2939-44 [9873651.001]
  • [Cites] J Hepatol. 2004 Nov;41(5):773-81 [15519650.001]
  • [Cites] J Hepatol. 2005 Jan;42(1):94-101 [15629513.001]
  • [Cites] Biol Pharm Bull. 2005 Jan;28(1):19-23 [15635156.001]
  • [Cites] Int J Mol Med. 2005 Feb;15(2):221-4 [15647834.001]
  • [Cites] Antioxid Redox Signal. 2005 Jan-Feb;7(1-2):32-41 [15650394.001]
  • [Cites] J Agric Food Chem. 2005 Jan 26;53(2):430-6 [15656684.001]
  • [Cites] Microbiol Immunol. 2005;49(2):139-47 [15722599.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2005 Jan;371(1):34-43 [15654598.001]
  • [Cites] BMC Pharmacol. 2005 Jan 31;5:2 [15683547.001]
  • [Cites] Mol Cell Biochem. 2005 May;273(1-2):69-78 [16013441.001]
  • [Cites] Shock. 2003 Jan;19(1):91-6 [12558151.001]
  • [Cites] Shock. 2003 Feb;19(2):150-6 [12578124.001]
  • [Cites] Pharmacol Toxicol. 2003 Jan;92(1):33-8 [12710595.001]
  • [Cites] Hepatology. 2003 May;37(5):1015-25 [12717382.001]
  • [Cites] Phytother Res. 2003 May;17(5):481-4 [12748983.001]
  • [Cites] Phytother Res. 2003 Sep;17(8):925-9 [13680826.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Oct;307(1):74-82 [12954792.001]
  • [Cites] J Biosci. 2003 Dec;28(6):715-21 [14660871.001]
  • [Cites] Mol Cell Biochem. 2003 Dec;254(1-2):289-97 [14674708.001]
  • [Cites] Free Radic Biol Med. 2003 Dec 15;35(12):1632-44 [14680686.001]
  • [Cites] Leukemia. 2004 Feb;18(2):276-84 [14671640.001]
  • [Cites] Biol Pharm Bull. 2004 Feb;27(2):170-3 [14758027.001]
  • [Cites] Biol Pharm Bull. 2004 Feb;27(2):198-202 [14758033.001]
  • [Cites] Inflamm Res. 2004 Mar;53(3):93-9 [15021963.001]
  • [Cites] Toxicol Lett. 2004 Jun 15;151(1):79-85 [15177643.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G310-4 [15246965.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2690-6 [15309720.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Oct;16(10):1017-25 [15371926.001]
  • [Cites] J Ethnopharmacol. 2004 Nov;95(1):31-7 [15374604.001]
  • [Cites] Biochem J. 1966 Jun;99(3):667-76 [5964963.001]
  • [Cites] Clin Chem. 1974 Apr;20(4):447-53 [4818198.001]
  • [Cites] Pharmacology. 1974;11(3):151-69 [4831804.001]
  • [Cites] J Biol Chem. 1975 Apr 25;250(8):2911-19 [804483.001]
  • [Cites] Z Klin Chem Klin Biochem. 1972 Jun;10(6):281-91 [4681028.001]
  • [Cites] Arch Biochem Biophys. 1978 Feb;186(1):189-95 [24422.001]
  • [Cites] Clin Chim Acta. 1980 Jul 17;105(1):145F-72F [7398084.001]
  • [Cites] Anal Biochem. 1982 Oct;126(1):131-8 [7181105.001]
  • [Cites] Zentralbl Bakteriol Mikrobiol Hyg A. 1985 Aug;260(1):108-12 [4060918.001]
  • [Cites] Surgery. 1987 Jun;101(6):746-52 [3589967.001]
  • [Cites] Annu Rev Biochem. 1988;57:505-18 [3052281.001]
  • [Cites] Arch Surg. 1989 Dec;124(12):1416-20; discussion 1420-1 [2589966.001]
  • [Cites] Am J Pathol. 1967 Aug;51(2):269-85 [4951803.001]
  • [Cites] J Leukoc Biol. 1990 Aug;48(2):123-8 [2164555.001]
  • (PMID = 16879252.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunosuppressive Agents; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / Nitrites; 0 / Tumor Necrosis Factor-alpha; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; IT942ZTH98 / Curcumin
  • [Other-IDs] NLM/ PMC1809677
  •  go-up   go-down


9. Ravindra S, Kini U: Cytomorphology and morphometry of small round-cell tumors in the region of the kidney. Diagn Cytopathol; 2005 Apr;32(4):211-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small round-cell tumors (SRCTs), with malignant cell components measuring 10 m or less in diameter with scanty cytoplasm in alcohol-fixed smears, pose a diagnostic challenge at fine-needle aspiration cytology (FNAC), especially when they are situated in and around the kidney and need facilities such as electron microscopy, immunohistochemistry, tissue culture, and cytogenetics for their subtyping.
  • A precise cytodiagnosis of SRCTs is important because a definite diagnosis is mandatory in preoperative diagnostic workup for presurgical chemotherapy in these cases.
  • With this view in mind, an attempt has been made to diagnose SRCTs in the region of the kidney based on cytomorphology and morphometry alone so as to facilitate its diagnosis in a simple cytology laboratory of a developing country where facilities for auxiliary techniques are not easily available.
  • An aspirate with preponderant malignant round cells that were larger or double the size of red blood cells in air-dried smears or measured less than 10 micro in diameter in alcohol-fixed smears was considered as a small blue-cell tumor.
  • Twenty-one were diagnosed as Wilms' tumor (WT), 10 were diagnosed as neuroblastoma (NB), 3 were ganglioneuroblastoma (GNB), 1 was a cellular congenital mesoblastic nephroma (CMN), and 1 was an adrenocortical carcinoma (ACC).
  • Aspirates from CMN and ACC were considered as simulators/mimickers of SRCT because they had superficial resemblance to SRCT and their differentiating cytomorphological features observed at histology were too subtle to be noted at cytology.
  • The latter were appreciated only on retrospective analysis after histological confirmation.Thus, morphometry in correlation with cytology, clinical history, physical findings, and radiological data is helpful in guided FNA for a definite diagnosis of SRCT in the region of the kidney.
  • One needs to keep in mind the mimickers of small round-cell lesions at this anatomic site.
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Child. Child, Preschool. Cytodiagnosis. Female. Humans. Infant. Infant, Newborn. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15754373.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Hadley GP, Mars M: Hypertension in a cohort of African children with renal tumours. Pediatr Surg Int; 2006 Mar;22(3):219-23
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypertension is a frequent problem in children with renal tumour, yet there are few reports from centres in the third world.
  • A retrospective study of blood pressure in a cohort of 46 patients with renal tumours seen over a 3-year period was carried out.
  • Fifty percent of patients presenting with Wilms' tumour were hypertensive.
  • Serum concentrations of active renin correlated poorly with blood pressure.
  • There was no correlation between serum concentrations of active renin and tumour mass or histology.
  • Specific antihypertensive therapy was offered to 11 patients who had either neurological or cardiac complications of hypertension.
  • All other patients with Wilms' tumour had their blood pressure controlled by neoadjuvant chemotherapy.
  • Patients with mesoblastic nephroma were managed by primary surgery.
  • Patients with asymptomatic hypertension may be monitored as hypertension will resolve with neoadjuvant chemotherapy.
  • Those with compelling symptomatology will require additional hypertensive medication.
  • [MeSH-major] Blood Pressure / physiology. Hypertension / epidemiology. Kidney Neoplasms / complications
  • [MeSH-minor] Africa / epidemiology. Biopsy, Needle. Child. Child, Preschool. Humans. Incidence. Infant. Infant, Newborn. Renin / blood. Retrospective Studies. Risk Factors. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pediatr Hematol Oncol. 1992 Aug;14(3):273-5 [1324619.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):78-80 [10695827.001]
  • [Cites] Am J Clin Oncol. 1993 Jun;16(3):201-5 [8393271.001]
  • [Cites] J Pediatr Surg. 1981 Feb;16(1):32-4 [6262473.001]
  • [Cites] J Pediatr Surg. 1972 Oct-Nov;7(5):573-6 [4343314.001]
  • [Cites] Med Pediatr Oncol. 1993;21(3):213-21 [8383282.001]
  • [Cites] Pediatr Cardiol. 1997 Jan-Feb;18(1):43-4 [8960492.001]
  • [Cites] J Pediatr Surg. 1987 Mar;22(3):278-80 [3031261.001]
  • [Cites] J Clin Pathol. 1984 Jul;37(7):738-42 [6086723.001]
  • [Cites] Indian Pediatr. 1991 Jul;28(7):811-2 [1666062.001]
  • [Cites] Med Pediatr Oncol. 1986;14(1):63-6 [3005817.001]
  • [Cites] J Pediatr Surg. 1989 Jun;24(6):599-600 [2544716.001]
  • [Cites] Nephrol Dial Transplant. 2005 Jan;20(1):231-4 [15328387.001]
  • [Cites] J Pediatr Surg. 1988 May;23(5):403-9 [2837560.001]
  • [Cites] Br J Urol. 1995 Aug;76(2):241-3 [7663919.001]
  • [Cites] J Pathol. 1996 Sep;180(1):71-3 [8943818.001]
  • [Cites] S Afr Med J. 1990 Jun 2;77(11):565-7 [2161132.001]
  • [Cites] AJR Am J Roentgenol. 1992 May;158(5):1161-2 [1314476.001]
  • (PMID = 16421703.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.23.15 / Renin
  •  go-up   go-down


11. Powis M: Neonatal renal tumours. Early Hum Dev; 2010 Oct;86(10):607-12
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presentation is usually as a flank mass or as a coincidental finding on either antenatal or postnatal ultrasound.
  • Mesoblastic nephroma is the most common tumour to be found at this age, but Wilms' tumour and other malignant and benign tumours occur.
  • Cross sectional imaging is useful to delineate the extent of the disease.
  • Given the low malignant potential of these tumours, treatment is by radical nephroureterctomy, except in cases with bilateral disease or syndromic patients with a high incidence of metachronous tumours.
  • Chemotherapy is rarely indicated.
  • Survival is generally excellent for all tumour types in this age group, the exception being malignant rhabdoid tumour of the kidney which may have metastases at presentation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Nephroma, Mesoblastic / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Anatomy, Cross-Sectional. Diagnosis, Differential. Genetic Predisposition to Disease. Humans. Imaging, Three-Dimensional. Infant, Newborn. Neuroblastoma / diagnosis. Practice Guidelines as Topic. Risk Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20888153.001).
  • [ISSN] 1872-6232
  • [Journal-full-title] Early human development
  • [ISO-abbreviation] Early Hum. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


12. Collins A, Demarche M, Dresse MF, Forget P, Lombet J, Jamblin P, Florkin B, Hoyoux C: [Renal tumors in children. A single center study of 31 cases]. Rev Med Liege; 2009 Nov;64(11):552-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les tumeurs rénales de l'enfant. Une etude monocentrique: a propos de 31 cas.
  • The mean age at diagnosis in our series was surprisingly higher than usually described: 25% of the patients were older than 8 years.
  • Moreover, a mesoblastic nephroma congenital kidney tumour--appeared in a 10 month old girl.
  • Our study shows that preoperative chemotherapy results in a less intensive treatment regimen conducting probably to less sequellae.
  • Event free survival and overall survival were respectively 87% and 94% at 10 years after diagnosis.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Hematuria / etiology. Humans. Infant. Infant, Newborn. Male. Nephrectomy. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20069968.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


13. Skotnicka-Klonowicz G, Bagłaj M, Sawicz-Birkowska K, Balcerska A, Dembowska B, Szymik-Kantorowicz S, Madziara W: [Nephroblastoma in children aged less than 6 months at diagnosis]. Med Wieku Rozwoj; 2003 Jul-Sep;7(3):347-57
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephroblastoma in children aged less than 6 months at diagnosis].
  • We present the results of treatment of kidney tumours in newborns and infants aged less than 6 months, in the years 1993-2000, from the Nephroblastoma Committee of the Polish Paediatric Group of Solid Tumours (PPGGL).
  • We have analysed the diagnostic and treatment results in the group of 31 children aged 0 to 6 months.
  • The accuracy of diagnosis based on imaging studies was 97%.
  • Only in one child the initial diagnosis of kidney tumour was not confirmed; cystic degeneration of kidney was finally established.
  • The tumours removed during surgery were small, with average size 213 cm3, and in half of the cases the size of the tumour did not exceed 165 cm3.
  • Primary complete excision of the tumour was performed in 21 children (67.7%).
  • In 10 cases histopathology confirmed mesoblastic nephroma, in 19 cases nephroblastoma and in 2 cases sarcoma clarocellulare.
  • In 10 infants (32.2%) with nephroblastoma delayed surgery preceded by chemotherapy was performed.
  • Indications for initial preoperative chemotherapy comprised: tumour in a single kidney, tumour in a horseshoe kidney, preoperative diagnostic biopsy of the tumour and large tumour in neonates older than 3 months.
  • In almost 70% of the children the stage of advancement was low (stage I and IIN-).
  • The tolerance of reduced chemotherapy by the infants was good. AS was 100%.
  • ESF for the 19 children registered for nephroblastoma between 1993 and 1996 for all stages of advancement and types of histology was 94.75%.
  • CONCLUSIONS:. 1) Mesoblastic nephroma and low risk nephroblastoma are the most common tumours in children within the first three years of life.
  • 2) The results of treatment of nephroblastoma in the youngest children (below 6 months of age) are the most favourable and represent world standards.3) Surgical complications in children operated primarily for nephroblastoma indicate the need of performing such operations in academic centres, specialised in newborn surgery.
  • 4) In infants with extensive kidney tumours older than 3 months, primarily considered as inoperative, individual induction chemotherapy should be taken into account.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Wilms Tumor / diagnosis. Wilms Tumor / therapy
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Nephroma, Mesoblastic / diagnosis. Nephroma, Mesoblastic / therapy. Poland. Retrospective Studies. Sarcoma, Clear Cell / diagnosis. Sarcoma, Clear Cell / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14963342.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Shet T, Viswanathan S: The cytological diagnosis of paediatric renal tumours. J Clin Pathol; 2009 Nov;62(11):961-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytological diagnosis of paediatric renal tumours.
  • Fine needle aspiration cytology (FNAC) is used for preoperative diagnosis of paediatric renal tumours, especially in centres where preoperative chemotherapy is advocated in Wilms' tumour.
  • This review focuses on salient cytological features in specific paediatric renal tumours, the approach to resolving a differential diagnosis and the role of ancillary methods in diagnosis of paediatric renal tumours.
  • Crucial differential diagnoses include distinguishing: Wilms' tumour from benign tumours in the kidney like multicystic nephroma or congenital mesoblastic nephroma; aggressive non-Wilms' tumours of kidney like rhabdoid tumour of kidney; and Wilms' tumour from other paediatric round cell sarcomas like neuroblastoma, non-Hodgkin lymphoma etc.
  • An approach based on classifying smears according to their cellular patterns as triphasic, round cell, spindle cell or epithelioid cell type assists in classifying paediatric renal tumours on cytology.
  • Immunocytochemistry for WT1, cytokeratin, synaptophysin, leucocyte common antigen and MIC2 will aid in evaluating round cell tumours in the renal region, while WT1, bcl2, vimentin and desmin will be useful for spindle cell tumours in that region.
  • A checklist of common tumours in a particular age group, relevant clinical information, awareness of distinctive and overlapping cytological features, and appropriate use of immunocytochemistry with cytogenetics go a long way in ensuring an accurate cytological diagnosis.
  • Used judiciously, FNAC is as effective a tool as a core biopsy for preoperative diagnosis of paediatric renal tumours, and with experience a 92% accuracy rate can be achieved.
  • [MeSH-major] Kidney Neoplasms / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Age Distribution. Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Infant, Newborn. Nephroma, Mesoblastic / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology. Sarcoma, Ewing / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700411.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


15. Miniati D, Gay AN, Parks KV, Naik-Mathuria BJ, Hicks J, Nuchtern JG, Cass DL, Olutoye OO: Imaging accuracy and incidence of Wilms' and non-Wilms' renal tumors in children. J Pediatr Surg; 2008 Jul;43(7):1301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pathologic reports from all tumor nephrectomies or open renal biopsies performed at a single institution from September 1999 to June 2005 were analyzed.
  • Sixty-eight had Wilms' tumor (WT) and 24 had an nWT.
  • The nWT group included congenital mesoblastic nephroma (5), clear cell sarcoma (4), neuroblastoma (4), renal cell carcinoma (4), lymphoma (2), angiomyolipoma (2), teratoma (1), hemangioma (1), and renal epithelial tumor (1).
  • Sensitivity, specificity, positive predictive value, and negative predictive value for computed tomography (CT) determining a diagnosis of WT were 0.92, 0.55, 0.84, and 0.73, respectively.
  • The CT reports explicitly stated a potential diagnosis in 89% of cases, with a diagnostic accuracy of 82%.
  • Preoperative imaging is of limited value in differentiating these tumors.
  • These data have significant implications for parental counseling, surgical plan, and the choice of neoadjuvant chemotherapy and argue in favor of obtaining a tissue diagnosis before instituting therapy.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Adolescent. Age Distribution. Biopsy. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639686.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ekinci S, Karnak I, Tanyel FC, Senocak ME, Kutluk T, Büyükpamukçu M, Büyükpamukçu N: Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors. Pediatr Surg Int; 2006 Mar;22(3):228-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors.
  • Hepatic resection is the main treatment modality for hepatic tumors in childhood.
  • The aim of this study is to report our experience in hepatic lobectomy, which is relatively rare procedure in childhood.
  • Age, gender, diagnosis, physical examination findings, results of preoperative laboratory investigations, radiological examination, resectability criteria, preoperative biopsies, chemotherapies, radiotherapies, postoperative pathological results, incisions, operation technique, intraoperative transfusions, drains used, antibiotic prophylaxes, and intraoperative and postoperative complications were evaluated for all patients.
  • Out of 25 patients with hepatic tumor seven patients with hepatoblastoma and four patients with hepatocellular carcinoma were given 5.7 +/- 0.3 cycles of chemotherapy before the operation.
  • Right lobectomy (n = 12), left lobectomy (n = 5), extended left lobectomy (n = 4), and extended right lobectomy (n = 3) and right lobectomy with enucleation of two masses from left lobe (n = 1) were performed.
  • Intraoperative blood transfusion of 30.7+/-6.0 ml/kg body weight was necessary.
  • Pathological examination of resected tumors revealed hepatoblastoma (n=11), mesenchymal hamartoma (n = 5), hepatocellular carcinoma (n = 4), hemangioendothelioma (n=1), malignant mesenchymal tumor (n = 1), hemangioma (n = 1), cyst adenoma (n = 1), and metastasis of cellular mesoblastic nephroma (n = 1).
  • Patients were observed in the intensive care unit for 3.4 +/- 0.3 days.
  • Safe hepatic resections with acceptable blood loss can be performed by a technique relying on good anatomic dissection and surgical control.
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatr Surg Int. 2006 Aug;22(8):695
  • [Cites] Eur Urol. 1997;32(2):194-7 [9286653.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1326-30 [1812268.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):386-91 [7796018.001]
  • [Cites] Ann Thorac Surg. 1991 May;51(5):717-21; discussion 721-2 [1850976.001]
  • [Cites] J Pediatr Surg. 1984 Oct;19(5):523-6 [6094781.001]
  • [Cites] Surg Gynecol Obstet. 1957 Sep;105(3):310-8 [13467662.001]
  • [Cites] J Surg Res. 1996 Feb 15;61(1):183-9 [8769964.001]
  • [Cites] Surgery. 1998 Apr;123(4):407-14 [9551066.001]
  • [Cites] Hum Pathol. 1983 Jun;14(6):512-37 [6303939.001]
  • [Cites] Chirurgie. 1986;112(5):337-42 [3608701.001]
  • [Cites] World J Surg. 1982 Jan;6(1):3-9 [7090393.001]
  • [Cites] J Pediatr Surg. 2000 Oct;35(10 ):1459-61 [11051151.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):330-42 [9015180.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1080-3; discussion 1083-4 [1328586.001]
  • [Cites] AJR Am J Roentgenol. 1993 Sep;161(3):572-3 [8352107.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] J Pediatr Surg. 2001 May;36(5):755-9 [11329582.001]
  • (PMID = 16395609.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


17. Levie NS, de Kraker J, Bökkerink JP, Appel IM, Aronson DC: SIOP treatment guidelines for renal tumours in small infants: fact or fantasy? Eur J Surg Oncol; 2000 Sep;26(6):567-70
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIOP treatment guidelines for renal tumours in small infants: fact or fantasy?
  • AIMS: Since as far back as 1980, SIOP (Société Internationale d>>Oncologie Pédiatrique) have advocated primary nephrectomy (PN) only for unilateral renal tumours in patients </=6 months of age.
  • Patients aged 7-12 months have been pre-treated with chemotherapy before nephrectomy is performed.
  • METHODS: Retrospective analysis of 67 patients under 12 months of age (1969-1995) with a unilateral renal tumour at diagnosis was carried out.
  • Demographics, pathology, staging and treatment variables were analysed.
  • RESULTS: Of 67 patients, 39 were male and 28 female.
  • Twenty-six (39%) infants were 0-6 months of age (group A) and 41 (61%) were 7-12 months old (group B).
  • In group A there were five patients (19%) with congenital mesoblastic nephroma (CMN), out of which one was still-born and therefore received no treatment, and 21 patients with a unilateral Wilms>> tumour (WT).
  • Fourteen of the 25 patients (56%) were treated with PN, including four patients with CMN.
  • In group B there was one patient (2%) with CMN and 40 patients with WT.
  • The percentage of pre-treated patients in group B increased after changing the protocol in 1980 to 81%.
  • In the age group included in the SIOP studies the protocol had been used significantly more often compared to the group included in the guidelines only.
  • The known excellent survival rate justifies a primary nephrectomy approach in the youngest age group, however, in cases of a large tumour, pre-operative chemotherapy in reduced doses may still be considered.
  • In our study fewer CMN were found (19%) than reported in the SIOP studies (20-70%), most likely due to a low registration rate, as a consequence of excluding this very young age group (0-6 months) from the SIOP protocol.
  • [MeSH-major] Guideline Adherence. Kidney Neoplasms / surgery. Nephrectomy. Nephroma, Mesoblastic / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Practice Guidelines as Topic. Preoperative Care. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11034807.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] ENGLAND
  •  go-up   go-down


18. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • A Wilms' tumor (WT) was present in 73 children.
  • 74% of patients (pats.) with WT survived (54 of 73 pats.).
  • Among patients with Wilms' tumors (WT), nephroblastoma (NB) of intermediate risk predominated (73%; 46 of 63 pats.).
  • Low-risk tumors occurred in 5 of 63 children (8%; mesoblastic nephroma 3, cystic partially diff.
  • High-risk WT were diagnosed in 12 of 63 patients (19%) (NB with anaplasia 10, clear cell sarcoma 1, malignant rhabdoid tumor 1).
  • We observed 3 children of school age with renal carcinoma and one patient with an intrarenal neuroblastoma.
  • The risk for relapses was 2.6-fold higher in patients with high-risk WT compared to the standard risk group.
  • Stages were re-evaluated according to SIOP 93-01.
  • Comparing relapse-free survival of stages I, II and III, respectively, there was a reduced survival rate for stage III (p=0.019).
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • In 3 patients preoperative diagnosis by means of imaging failed.
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • 2 patients of the preoperative group died (focal anaplastic NB).
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stöckle M, Thüroff JW, Tröger J, Weirich A, von Schweinitz D, Zoubek A, Graf N: Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Padiatr; 2004 May-Jun;216(3):132-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
  • BACKGROUND: The treatment of Wilms Tumor is integrated into clinical trials since the 1970's.
  • In contrast to the National Wilms Tumor Study Group (NWTSG) the SIOP trials and studies largely focus on the issue of preoperative therapy to facilitate surgery of a shrunken tumor and to treat metastasis as early as possible.
  • PATIENTS AND METHODS: In the SIOP 93-01/GPOH trial and study 1 020 patients with a newly diagnosed renal tumor were registered.
  • 847 of them had a histological proven Wilms Tumor, of whom 637 were unilateral localized, and 173 tumors had an other histology [40 congenital mesoblastic nephroma (CMN), 51 clear cell sarcoma (CCSK), 24 rhabdoid tumor (RTK) and 58 other tumors].
  • Preoperative chemotherapy in benign tumors was given to 1.3 % of the patients.
  • The main objective of the trial was the randomized question, if the postoperative two drug chemotherapy for stage I in intermediate risk or anaplasia can be reduced from conventional 3 courses to an experimental 1 course without loss of efficacy.
  • RESULTS: 519 patients with unilateral nonmetastatic Wilms did receive preoperative chemotherapy.
  • The histology in this group of patients was of intermediate risk in 469 (90 %) patients, 14 (3 %) tumors were low risk and 36 (7 %) high risk.
  • The stage distribution of the tumors was stage I in 315 (61 %), stage II N- in 126 (24 %), stage II N+ in 25 (5 %) and stage III in 36 (7 %) patients.
  • In 17 (3 %) patients the tumor stage remained unclear.
  • Tumor volume was measured in 487 patients before and in 402 after preoperative chemotherapy.
  • The median tumor volume did shrink from 353 to 126 ml.
  • The event free survival (EFS) after 5 years was 91 % for all patients with unilateral Wilms tumor without distant metastasis.
  • Randomisation was done in 43.7 % for stage I patients and there was no difference in EFS for both treatment arms (90 versus 91 %).
  • The EFS is identical for patients with stage I and II N- (0.92), as well as for stage II N+ and III (0.82).
  • The tumor volume after chemotherapy is a prognostic factor for intermediate risk tumors with the exception of epithelial and stromal predominant tumors.
  • These two subtypes often present as large tumors, they do not shrink during preoperative chemotherapy but they still have an excellent prognosis.
  • On the other hand the prognosis of patients with blastemal predominant subtype after preoperative chemotherapy is worse than in any other patient group of intermediate risk tumors.
  • There are less blastemal predominant tumors compared to primary surgery, but they are chemotherapeutic resistant selected by the preoperative chemotherapy.
  • CONCLUSION: Patients with unilateral Wilms tumor without metastasis have an excellent prognosis.
  • The post-operative chemotherapy in stage I can be reduced to 4 weeks without worsening treatment outcome.
  • The reduction of the tumor volume could be identified as a helpful marker for stratification of post-operative treatment.
  • Post-chemotherapy blastemal predominant subtype of Wilms tumor has to be classified as high risk tumor.
  • Focal anaplasia has a better prognosis than diffuse anaplasia and will be classified as intermediate risk tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Neoadjuvant Therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Nephrectomy. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / mortality. Nephroma, Mesoblastic / pathology. Nephroma, Mesoblastic / surgery. Prognosis. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / mortality. Rhabdoid Tumor / pathology. Rhabdoid Tumor / surgery. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / mortality. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175957.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


20. Indap MA, Radhika S, Motiwale L, Rao KV: Inhibitory effect of cinnamoyl compounds against human malignant cell line. Indian J Exp Biol; 2006 Mar;44(3):216-20
Hazardous Substances Data Bank. CURCUMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of cinnamoyl compounds against human malignant cell line.
  • In the present study, anti-proliferative effects of dietary polyphenolic compounds have been observed and demonstrated the strong anticancer efficacy of curcumin (CMN), an active constituent of dietary spice (turmeric) using human leukemia cancer cell line.
  • CMN inhibited the proliferation of K562 leukemic cells by induction of apoptosis.
  • The current study demonstrated synergy with combination of drug therapy, and suggested that combination of ferulic acid and cisplatin synergistically inhibited cellular proliferation.
  • Cytotoxic synergy was observed independent of the sequence of addition of two drugs to cultured cells.
  • The synergized growth inhibitory effect with cisplatin was probably associated with G2-M arrest in cell cycle progression.
  • These findings suggested that among the cinnamoyl compounds, CMN was most potent and FER appeared to be a better modulating agent on human malignant cell line.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Cell Cycle / drug effects. Curcuma / chemistry. Curcumin / chemistry. Curcumin / pharmacology. Leukemia, Erythroblastic, Acute / pathology
  • [MeSH-minor] Cell Proliferation / drug effects. Cisplatin / chemistry. Cisplatin / pharmacology. Cyclodextrins / chemistry. Cyclodextrins / pharmacology. Flavonoids / chemistry. Flavonoids / pharmacology. Humans. K562 Cells. Phenols / chemistry. Phenols / pharmacology. Polyphenols

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538860.001).
  • [ISSN] 0019-5189
  • [Journal-full-title] Indian journal of experimental biology
  • [ISO-abbreviation] Indian J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclodextrins; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; IT942ZTH98 / Curcumin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Morota N, Ihara S, Deletis V: Intraoperative neurophysiology for surgery in and around the brainstem: role of brainstem mapping and corticobulbar tract motor-evoked potential monitoring. Childs Nerv Syst; 2010 Apr;26(4):513-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NEUROPHYSIOLOGICAL TECHNIQUES: Brainstem mapping (BSM) is applied to locate cranial nerves and their motor nuclei (CMN) on the floor of the fourth ventricle.
  • Corticobulbar tract (CBT) motor-evoked potential (MEP) monitoring is used to achieve on-line monitoring of the cranial motor nerves' functional integrity.
  • DISCUSSION: Each of these procedures bears a specific role: BSM can help avoid direct damage to CMNs on the fourth ventricular floor; CBT-MEP can provide simultaneous feedback on the functional integrity of the CBT and CMN during surgery, eventually leading to "tailored" modifications of the surgical procedure, based upon neurophysiological responses.
  • [MeSH-minor] Brain Mapping / methods. Brain Neoplasms / physiopathology. Brain Neoplasms / surgery. Brain Neoplasms / therapy. Child, Preschool. Ependymoma / physiopathology. Ependymoma / surgery. Ependymoma / therapy. Evoked Potentials, Motor. Female. Humans. Infant. Male. Pyramidal Tracts / physiopathology. Pyramidal Tracts / surgery. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / physiopathology. Rhabdoid Tumor / surgery. Teratoma / drug therapy. Teratoma / physiopathology. Teratoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Tech Stand Neurosurg. 1995;22:261-341 [7495420.001]
  • [Cites] Neurosurgery. 1996 Oct;39(4):787-93; discussion 793-4 [8880774.001]
  • [Cites] Brain. 2001 Sep;124(Pt 9):1866-76 [11522588.001]
  • [Cites] Neurosurgery. 2000 Nov;47(5):1170-6; discussion 1176-7 [11063111.001]
  • [Cites] Childs Nerv Syst. 2002 Jul;18(6-7):264-87 [12172930.001]
  • [Cites] Pediatr Neurosurg. 1996;24(1):24-34 [8817612.001]
  • [Cites] Acta Neurochir (Wien). 2006 May;148(5):499-509; discussion 509 [16374568.001]
  • [Cites] Neurosurgery. 1995 Nov;37(5):922-9; discussion 929-30 [8559341.001]
  • [Cites] J Neurosurg. 1993 Sep;79(3):393-9 [8360737.001]
  • [Cites] Clin Neurophysiol. 2005 Mar;116(3):588-96 [15721072.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):1129-43; discussion 1129-43 [16723892.001]
  • [Cites] Childs Nerv Syst. 2008 Nov;24(11):1307-14 [18563419.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):262-5 [10896707.001]
  • (PMID = 20143075.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 18
  •  go-up   go-down


22. Mishima M, Tanaka K, Takeiri A, Harada A, Kubo C, Sone S, Nishimura Y, Tachibana Y, Okazaki M: Two structurally distinct inhibitors of glycogen synthase kinase 3 induced centromere positive micronuclei in human lymphoblastoid TK6 cells. Mutat Res; 2008 Aug 25;643(1-2):29-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two structurally distinct inhibitors of glycogen synthase kinase 3 induced centromere positive micronuclei in human lymphoblastoid TK6 cells.
  • Glycogen synthase kinase 3 (GSK3) is an attractive novel pharmacological target.
  • Inhibition of GSK3 is recently regarded as one of the viable approaches to therapy for Alzheimer's disease, cancer, diabetes mellitus, osteoporosis, and bipolar mood disorder.
  • Here, we have investigated the aneugenic potential of two potent and highly specific inhibitors of GSK3 by using an in vitro micronucleus test with human lymphoblastoid TK6 cells.
  • One inhibitor was a newly synthesized maleimide derivative and the other was a previously known aminopyrimidine derivative.
  • One hundred micronuclei (MN) of each were analyzed using centromeric DNA staining with fluorescence in situ hybridization.
  • Both the two structurally distinct compounds induced centromere-positive micronuclei (CMN).
  • Calculated from the frequency of MN cells and the percentage of CMN, CMN cell incidence after treatment with the maleimide compound at 1.2 microM, 2.4 microM, and 4.8 microM was 11.6, 27.7, and 56.3 per 1000 cells, respectively; the negative control was 4.5.
  • CMN cell incidence after the treatment with the aminopyrimidine compound at 1.8 microM, 3.6 microM, and 5.4 microM was 6.7, 9.8 and 17.2 per 1000 cells, respectively.
  • The frequency of CMN cells correlated well with mitotic cell incidence after treatment with either compound.
  • These results lend further support to the hypothesis that the inhibition of GSK3 activity affects microtubule function and exhibits an aneugenic mode of action.
  • [MeSH-major] Aneugens / pharmacology. Centromere / drug effects. Enzyme Inhibitors / pharmacology. Glycogen Synthase Kinase 3 / antagonists & inhibitors. Lymphocytes / drug effects. Pyrimidines / pharmacology
  • [MeSH-minor] Blotting, Western. Cell Nucleus / genetics. Flow Cytometry. Fluorescent Antibody Technique. Humans. In Situ Hybridization, Fluorescence / methods. Maleimides / pharmacology. Micronucleus Tests / methods. Microtubules / physiology. Spindle Apparatus / drug effects. Spindle Apparatus / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18598706.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aneugens; 0 / Enzyme Inhibitors; 0 / Maleimides; 0 / Pyrimidines; 541-59-3 / maleimide; 591-54-8 / 4-aminopyrimidine; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  •  go-up   go-down


23. Sawicz-Birkowska K, Czernik J, Bagłaj M, Czauderna P, Kantorowicz-Szymik S, Poznański WA, Mańkowski P, Madziara W, Prokurat A, Osemlak J: [Renal neoplasms in children]. Przegl Lek; 2004;61 Suppl 2:20-3
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephroblastoma is the most common kidney tumor in Polish children.
  • MATERIAL: 500 pts with nephroblastoma and 33 of non-Wilms: CMN, RCC,CSSK, RTK and others tumors were registered, mean age 4.5 years between 1993 till 2002.
  • Stage: CS I--148, CS II--191, CS III--114, CS IV--51, CS V--29 pts.
  • All pts with nephroblastoma were treated according to the first national PPGGL 01-92 protocol with pre-operative chemotherapy (ACT, VCR) for CS I-III and ACT, VCR, DOX in pts of stage IV, over the age of 6 months.
  • Pre-operative chemotherapy was done to 93.8% pts.
  • RESULTS: Radical nephrectomy post pre op chemotherapy was performed in 451 (98%) pts over 6 months and in 44 (8.2%) infants less than 6 months with nephroblastoma.
  • Partial nephrectomy for unilateral tumor post preoperative chemotherapy was made in 6 (1.2%).
  • The results of treatment of 33 pts with non-Wilms renal tumors have improved lately.
  • CONCLUSIONS: The use of systemic neoadjuvant chemotherapy in all pts over 6 months according to the recommendation of SIOP Nephroblastoma protocol (01-92) produced tumor shrinkage, facilitated complete surgical nephrectomy, and was very advantageous in the treatment of renal tumors in children.
  • The results of treatment of non-Wilms tumor have also improved thanks to introduction of new and more aggressive regimens of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / drug therapy. Wilms Tumor / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Neoadjuvant Therapy. Neoplasm Staging. Poland. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686041.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


24. Stehr M, Deilmann K, Haas RJ, Dietz HG: Surgical complications in the treatment of Wilms' tumor. Eur J Pediatr Surg; 2005 Dec;15(6):414-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical complications in the treatment of Wilms' tumor.
  • We present our data on the treatment of Wilms' Tumor (WT) with an emphasis on both the positive effect and the adverse effect of preoperative chemotherapy with regard to surgical intervention.
  • 57 % received preoperative chemotherapy (ChTx) and 43 % were operated on primarily.
  • After preoperative ChTx 54 % of the cases were regrouped as stage I, whereas after primary operation 46 % of the patients were grouped as stage I, thus indicating a downstaging with preoperative ChTx.
  • In 8 % of the patients with preoperative chemotherapy intraoperative complications occurred with a rupture of the tumor in 1 case.
  • In contrast, there were intraoperative complications in 25 % of the patients with a primary operation with rupture of the tumor in 3 cases.
  • 1 child (1.5 %) was treated with chemotherapy who did not have a Wilms' tumor but a benign nephroma (CMN).
  • 3 cases had a clear cell sarcoma (CCSK) and in one case histology revealed a rhabdoid tumor (MRTK).
  • In one case of CCSK only histology of the metastases disclosed the correct diagnosis.
  • Irrespective of the known adverse effects such as changing tumor histology, which may affect the correct staging, and the remaining risk of an initial inadequate treatment, our data show that the regimen of preoperative chemotherapy as proposed by the SIOP study should not be abandoned.
  • However, the relatively small number of our patients does not allow a significant statement to be made but confirms the results of past SIOP studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intraoperative Complications. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / drug therapy. Wilms Tumor / surgery
  • [MeSH-minor] Child, Preschool. Dactinomycin / administration & dosage. Humans. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418959.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine
  •  go-up   go-down


25. Little SE, Bax DA, Rodriguez-Pinilla M, Natrajan R, Messahel B, Pritchard-Jones K, Vujanic GM, Reis-Filho JS, Jones C: Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4360-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase overexpressed in a variety of human malignancies, against which targeted therapies have shown efficacy in lung and brain tumors.
  • EXPERIMENTAL DESIGN: We screened a series of 307 pediatric renal tumors for EGFR expression by immunohistochemistry and gene amplification by chromogenic in situ hybridization.
  • In identifying a striking predilection for certain tumor types, we further analyzed the clear cell sarcomas of the kidney (CCSK) for mutations in EGFR and PTEN.
  • In addition, 5 of 9 (55.6%) mesoblastic nephromas and 12 of 12 (100%) CCSKs were strongly immunoreactive for EGFR.
  • In studying the CCSKs in more detail, we identified gene amplification in 1 of 12 (8.3%) cases and a somatic T790M EGFR mutation in a further case.
  • Identification of factors predictive of poor response to targeted therapy, including the drug resistance T790M mutation, may provide a rationale for upfront trials with irreversible inhibitors of EGFR in children with these tumors.
  • [MeSH-minor] Child, Preschool. Gene Amplification. Humans. Immunoenzyme Techniques. In Situ Hybridization. Infant. Mutation. Nephroma, Mesoblastic / metabolism. Nephroma, Mesoblastic / pathology. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Rhabdoid Tumor / metabolism. Rhabdoid Tumor / pathology. Tissue Array Analysis. Wilms Tumor / metabolism. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646270.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down






Advertisement